VIVES, a high-tech early-stage firm based in Louvain-la-Neuve, Belgium, has raised €38M in the second closing of its VIVES IUF fund, bringing total funding to €70M. The European Investment Fund (EIF), a current shareholder in VIVES, committed €25M alongside current and new blue-chip investors.
VIVES IUF is focused on catalyzing science into startups, with a particular emphasis on high-potential spin-offs from the Université catholique de Louvain (UCLouvain). The fund invests in the early stages of startups, providing capital and mentoring to help them grow and ultimately succeed in the market.
The additional funding will be used to support the growth of the existing portfolio of startups within VIVES IUF, as well as to identify and invest in new startups. The fund aims to capitalize on the strong research and development capabilities of UCLouvain and support innovative companies with high-growth potential.
VIVES IUF has already made several investments in promising startups, including those in the life sciences, digital health, and technology sectors. The fund has a team of experienced investors and industry experts who provide guidance and support to the startups they invest in.
This latest funding round, led by the EIF, is a testament to the success and potential of VIVES IUF. The fund has already demonstrated its ability to identify and nurture high-potential startups, and this additional capital will allow it to continue supporting the growth and development of innovative companies in Belgium.
Overall, VIVES IUF’s €70M equity injection will help drive the transformation of scientific discoveries into successful startups. By providing the necessary funding and expertise, the fund enables researchers and entrepreneurs to bring their innovative ideas to market and contribute to the growth and competitiveness of the Belgian economy.
